SUITOR

SUITOR estimates the optimal number of de novo mutational signatures in cancer genomics datasets using an unsupervised cross-validation framework to guide signature selection.


Key Features:

  • De novo mutational signature analysis: Performs de novo extraction of mutational signatures from mutation catalogs.
  • Optimal signature number selection: Determines the optimal number of mutational signatures present in a dataset.
  • Unsupervised cross-validation: Employs an unsupervised cross-validation methodology to evaluate signature models.
  • Minimizes assumptions: Minimizes methodological assumptions during cross-validation.
  • Avoids numerical approximations: Avoids numerical approximations to reduce potential estimation bias.
  • Prediction-error minimization: Selects signatures by identifying models with the smallest prediction errors.
  • Overfitting reduction: Reduces the risk of overfitting through its cross-validation-based selection criterion.
  • Validation in vitro and in silico: Performance has been validated using in vitro experiments and in silico simulations.
  • Application to whole-genome sequencing: Has been applied to 2,540 whole-genome sequenced tumors across 22 cancer types.
  • Independent breast cancer corroboration: Identified signatures were corroborated in an independent breast cancer study.

Scientific Applications:

  • Etiological inference: Supports inference of mutational processes underlying cancer development.
  • Therapeutic implication analysis: Facilitates investigation of potential therapeutic implications of mutational signatures.
  • Large-cohort signature discovery: Enables signature discovery and selection in large whole-genome sequencing cohorts, including multi-cancer and breast cancer studies.
  • Downstream analytical accuracy: Improves accuracy of downstream analyses that depend on correct signature number estimation.

Methodology:

Performs de novo mutational signature extraction combined with an unsupervised cross-validation framework that minimizes assumptions, avoids numerical approximations, and selects the number of signatures by minimizing prediction error.

Topics

Details

License:
Not licensed
Cost:
Free of charge
Tool Type:
library
Operating Systems:
Mac, Linux, Windows
Programming Languages:
R
Added:
7/14/2022
Last Updated:
11/24/2024

Operations

Publications

Lee D, Wang D, Yang XR, Shi J, Landi MT, Zhu B. SUITOR: Selecting the number of mutational signatures through cross-validation. PLOS Computational Biology. 2022;18(4):e1009309. doi:10.1371/journal.pcbi.1009309. PMID:35377867. PMCID:PMC9009674.

PMID: 35377867
PMCID: PMC9009674
Funding: - national cancer institute: Intramural Research Program